HSPG2 Mutation Association with Immune Checkpoint Inhibitor Outcome in Melanoma and Non-Small Cell Lung Cancer.

MLA

Zhang, Wenjing, et al. “HSPG2 Mutation Association with Immune Checkpoint Inhibitor Outcome in Melanoma and Non-Small Cell Lung Cancer.” Cancers, vol. 14, no. 14, July 2022, p. N.PAG. EBSCOhost, https://doi.org/10.3390/cancers14143495.

APA

Zhang, W., Lin, Z., Shi, F., Wang, Q., Kong, Y., Ren, Y., Lyu, J., Sheng, C., Li, Y., Qin, H., Wang, S., & Wang, Q. (2022). HSPG2 Mutation Association with Immune Checkpoint Inhibitor Outcome in Melanoma and Non-Small Cell Lung Cancer. Cancers, 14(14), N.PAG. https://doi.org/10.3390/cancers14143495

Chicago

Zhang, Wenjing, Zhijuan Lin, Fuyan Shi, Qiang Wang, Yujia Kong, Yanfeng Ren, Juncheng Lyu, et al. 2022. “HSPG2 Mutation Association with Immune Checkpoint Inhibitor Outcome in Melanoma and Non-Small Cell Lung Cancer.” Cancers 14 (14): N.PAG. doi:10.3390/cancers14143495.